← Leaderboards
Steven L Wechsler
Cedars-Sinai Medical Center
$12,074,225
Attributed
$12,074,225
Total exposure
9
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $877.9K · FY2005–15$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
Funding mix
By agency
NIH$12,074,225 · 9
By mechanism
R01$10,887,879 · 5
R56$803,096 · 2
R21$231,750 · 1
R03$151,500 · 1
Top collaborators
No co-investigators on record.
Most similar at Cedars-Sinai Medical Center
Same institution · by research overlap
- Homayon Ghiasi$23,295,165
- Guey-Chuen Perng$1,841,413
- Anthony Bart Nesburn$4,151,152
- Alexander V Ljubimov$16,915,625
Others in their field
Top investigators on “Cornea”
- Raymond Kraker · Jaeb Center For Health Research, Inc.$47,584,981
- Ehud Isacoff · University Of California Berkeley$23,946,000
- Mary Ann Stepp · George Washington University$18,098,163
- Keri Hammel · The Emmes Company, Llc$17,992,237
- Reza Dana · Schepens Eye Research Institute$17,808,908
- Eric Pearlman · Case Western Reserve University$16,337,424
Research focus
CorneaHerpes Simplex Virus 1Laboratory RabbitGene ExpressionRelapse /RecurrencePolymerase Chain ReactionLatent Virus InfectionGenetic MappingNeuronsBlindnessApoptosisHerpesvirus 1, HumanVirusLeadMolecularOcular HerpesMutantOryctolagus CuniculusInfectionGenesRecurrenceViralVirus ProteinNucleic Acid Sequence
Grant awards (31)
LAT-HVEM Interactions Effect HSV-1 Latency/Reactivation$231,750
R21 · FY2015 · AI · contact PI
Corneal HSV-1: LAT's Anti-Apoptosis Activity and Latency$453,576
R01 · FY2013 · EY · contact PI
HSV-1 LAT miRNAs: Neurovirulence, reactivation, mechanism$420,596
R56 · FY2013 · AI · contact PI
Corneal HSV-1: LAT's Anti-Apoptosis Activity and Latency$477,449
R01 · FY2012 · EY · contact PI
Corneal HSV-1: LAT's Anti-Apoptosis Activity and Latency$477,449
R01 · FY2011 · EY · contact PI
Corneal HSV-1: Newly discovered LAT miRNAs and latency$382,500
R56 · FY2011 · AI · contact PI
Corneal HSV-1: LAT's Anti-Apoptosis Activity and Latency$489,846
R01 · FY2010 · EY · contact PI
Corneal HSV-1: Immunopathologic Mechanisms of HSK$378,675
R01 · FY2010 · EY · contact PI
Corneal HSV-1: LAT's Anti-Apoptosis Activity and Latency$487,316
R01 · FY2009 · EY · contact PI
Corneal HSV-1: Immunopathologic Mechanisms of HSK$381,875
R01 · FY2009 · EY · contact PI
Corneal HSV-1: LAT's Anti-Apoptosis Activity and Latency$496,624
R01 · FY2008 · EY · contact PI
Corneal HSV-1: Immunopathologic Mechanisms of HSK$381,250
R01 · FY2008 · EY · contact PI
Corneal HSV-1: LAT's Anti-Apoptosis Activity and Latency$496,404
R01 · FY2007 · EY · contact PI
Corneal HSV-1: LAT's Anti-Apoptosis Activity and Latency$489,087
R01 · FY2006 · EY · contact PI
Corneal HSV-1: LAT's Anti-Apoptosis Activity and Latency$529,470
R01 · FY2005 · EY
Corneal HSV-1: LAT Blocks Apoptosis in Rabbit TG$413,616
R01 · FY2004 · EY
CORNEAL HSV-1: A NOVEL VIRULENCE/REACTIVATION GENE$366,763
R01 · FY2004 · EY
Ocular HSV-1: Preventing Recurrent Corneal Disease$151,500
R03 · FY2004 · EY
Corneal HSV-1: LAT Blocks Apoptosis in Rabbit TG$808,125
R01 · FY2003 · EY
CORNEAL HSV-1: A NOVEL VIRULENCE/REACTIVATION GENE$498,072
R01 · FY2003 · EY
Corneal HSV-1: LAT Blocks Apoptosis in Rabbit TG$401,567
R01 · FY2003 · EY
Corneal HSV-1: LAT Blocks Apoptosis in Rabbit TG$462,008
R01 · FY2002 · EY
CORNEAL HSV-1: A NOVEL VIRULENCE/REACTIVATION GENE$445,800
R01 · FY2002 · EY
CORNEAL HSV-1: A NOVEL VIRULENCE/REACTIVATION GENE$295,261
R01 · FY2002 · EY
CORNEAL HSV-1: A NOVEL VIRULENCE/REACTIVATION GENE$50,796
R01 · FY2002 · EY
Corneal HSV-1: LAT Blocks Apoptosis in Rabbit TG$424,416
R01 · FY2001 · EY
CORNEAL HSV-1: A NOVEL VIRULENCE/REACTIVATION GENE$335,977
R01 · FY2001 · EY
CORNEAL HSV-1: A NOVEL VIRULENCE/REACTIVATION GENE$58,518
R01 · FY2001 · EY
OCULAR HSV INFECTION--LATENCY AND REACTIVATION$425,909
R01 · FY2000 · EY
CORNEAL HSV-1: A NOVEL VIRULENCE/REACTIVATION GENE$326,190
R01 · FY2000 · EY
CORNEAL DISEASE--ROLE OF THE NEWLY DESCRIBED HSV 1 ORF P$35,840
R01 · FY2000 · EY